Boston Scientific Prices $3.0B Four-Tranche Senior Notes to Fund Penumbra Deal
BSX is trading near its 52-week low of $39.57 (8.8% above the low).
Summary
Boston Scientific priced $3.0 billion of senior notes in four fixed-rate tranches (5.375%-5.875%) to help fund the ~$14.5 billion Penumbra acquisition, settling December 1, 2026, with a 101% special mandatory redemption if the deal fails.
Key Events · Financing and Capital Events · BSX
-
USD Notes Priced at $3.0B
Four fixed-rate tranches: $1.0B 3-year at 5.375%, $750M 5-year at 5.500%, $750M 7-year at 5.750% and $500M 10-year at 5.875%, priced at 99.798 to 99.972.
-
Proceeds Fund Penumbra Cash Consideration
Net proceeds, together with the concurrent euro notes, short-term borrowings and cash on hand, finance the cash consideration for the ~$14.5 billion Penumbra Acquisition and related fees.
-
Deal-Failure Redemption at 101%
If the Penumbra Acquisition is not completed by the Special Mandatory Redemption End Date, each series must be redeemed at 101% of principal plus accrued interest.
-
Settlement December 1, 2026
Trade date November 19, 2026 with T+7 settlement on December 1, 2026; first interest payment June 1, 2027.
Analysis · BSX · Industrial Applications And Services
Boston Scientific has locked in $3.0 billion of USD senior notes at coupons of 5.375% to 5.875%, the dollar leg of the financing for its roughly $14.5 billion Penumbra acquisition. Because the notes carry a special mandatory redemption at 101% of principal if the Penumbra deal is not completed by the stated end date, bondholders are effectively underwriting deal-completion risk rather than pure Boston Scientific credit. For equity holders the takeaway is leverage: this stacks on top of the €4.25 billion of euro notes priced earlier today, and the blended cost of that debt is a real, recurring drag on earnings. Ratings sit at A3/A-/A- with negative outlooks at Moody's and S&P, so the acquisition is already pressuring the credit profile.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $43.07 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $62.3B. The 52-week trading range was $39.57 to $101.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.